Recent submissions

  • Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. 

    Pearson, A; Proszek, PZ; Pascual, J; Fribbens, C; Shamsher, MK; Kingston, B; O'Leary, B; Herrera-Abreu, MT; Cutts, RJ; Garcia-Murillas, I; Bye, H; Walker, BA; Gonzalez De Castro, D; Yuan, L; Jamal, S; Hubank, M; López-Knowles, E; Schuster, EF; Dowsett, M; Osin, P; Nerurkar, A; Parton, M; Okines, AF; Johnston, SRD; Ring, A; Turner, NC (2019-10-07)
    PURPOSE: Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential ...
  • Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors. 

    Leal, MF; Haynes, BP; Schuster, EF; Yeo, B; Afentakis, M; Zabaglo, L; Martins, V; Buus, R; Dodson, A; Cheang, MCU; Smith, IE; Martin, L-A; Dowsett, M (2019-09-23)
    PURPOSE: To investigate the presence of ESR1 mutation in primary oestrogen-receptor positive breast cancer (ER+BC) treated with extended (>4 weeks) neoadjuvant (pre-surgical) aromatase inhibitor (NAI) therapy and to identify ...
  • High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. 

    Anderhub, SJ; Mak, GW-Y; Gurden, MD; Faisal, A; Drosopoulos, K; Walsh, K; Woodward, HL; Innocenti, P; Westwood, IM; Naud, S; Hayes, A; Theofani, E; Filosto, S; Saville, H; Burke, R; van Montfort, RLM; Raynaud, FI; Blagg, J; Hoelder, S; Eccles, SA; Linardopoulos, S (2019-10)
    BOS172722 (CCT289346) is a highly potent, selective, and orally bioavailable inhibitor of spindle assembly checkpoint kinase MPS1. BOS172722 treatment alone induces significant sensitization to death, particularly in highly ...
  • Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species. 

    Wood, FL; Shepherd, S; Hayes, A; Liu, M; Grira, K; Mok, Y; Atrash, B; Faisal, A; Bavetsias, V; Linardopoulos, S; Blagg, J; Raynaud, FI (2019-11-01)
    CCT241736 is a dual fms-like tyrosine kinase 3 (FLT3)/Aurora kinase inhibitor in development for the treatment of acute myeloid leukaemia. The successful development of any new drug relies on adequate safety testing including ...
  • De novo phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy. 

    Andrejeva, G; Gowan, S; Lin, G; Wong Te Fong, A-CL; Shamsaei, E; Parkes, HG; Mui, J; Raynaud, FI; Asad, Y; Vizcay-Barrena, G; Nikitorowicz-Buniak, J; Valenti, M; Howell, L; Fleck, RA; Martin, L-A; Kirkin, V; Leach, MO; Chung, Y-L (2019-09-13)
    Macroautophagy/autophagy can enable cancer cells to withstand cellular stress and maintain bioenergetic homeostasis by sequestering cellular components into newly formed double-membrane vesicles destined for lysosomal ...
  • A decade of clinical development of PARP inhibitors in perspective. 

    Mateo, J; Lord, CJ; Serra, V; Tutt, A; Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; Oaknin, A; Kaye, SB; de Bono, JS (2019-09-01)
    Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce ...
  • Acquired genetic events and NF1 mutations in advanced breast cancer 

    Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, M; Kingston, B; O'Leary, B; Herrera-Abreu, M; Cutts, R; Garcia-Murillas, I; Bye, H; Walker, B; Gonzalez, D; Yuan, L; Jamal, S; Hubank, M; Lopez-Knowles, E; Schuster, E; Dowsett, M; Osin, P; Nerurkar, A; Parton, M; Okines, A; Johnston, S; Ring, A; Turner, N
  • Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial. 

    Hrebien, S; Citi, V; Garcia-Murillas, I; Cutts, R; Fenwick, K; Kozarewa, I; McEwen, R; Ratnayake, J; Maudsley, R; Carr, TH; de Bruin, EC; Schiavon, G; Oliveira, M; Turner, NC (2019-03-12)
    BACKGROUND: Dynamic changes in circulating tumour DNA (ctDNA) levels may predict long-term outcome. We utilised samples from a phase I/II randomised trial (BEECH) to assess ctDNA dynamics as a surrogate for progression ...
  • Early enrichment of ESR1 mutations and the impact on gene expression in primary breast cancer treated with aromatase inhibitors in the pre-surgical setting 

    Dowsett, M; Ferreira Leal, M; Haynes, B; Schuster, E; Yeo, B; Afentakis, M; Zabaglo, L; Martins, V; Buus, R; Dodson, A; Cheang, M; Smith, I; Martin, L-A
  • Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. 

    Leung, SCY; Nielsen, TO; Zabaglo, LA; Arun, I; Badve, SS; Bane, AL; Bartlett, JMS; Borgquist, S; Chang, MC; Dodson, A; Ehinger, A; Fineberg, S; Focke, CM; Gao, D; Gown, AM; Gutierrez, C; Hugh, JC; Kos, Z; Laenkholm, A-V; Mastropasqua, MG; Moriya, T; Nofech-Mozes, S; Osborne, CK; Penault-Llorca, FM; Piper, T; Sakatani, T; Salgado, R; Starczynski, J; Sugie, T; van der Vegt, B; Viale, G; Hayes, DF; McShane, LM; Dowsett, M; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG) (2019-08)
    AIMS: The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The ...
  • Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. 

    Abubakar, M; Figueroa, J; Ali, HR; Blows, F; Lissowska, J; Caldas, C; Easton, DF; Sherman, ME; Garcia-Closas, M; Dowsett, M; Pharoah, PD (2019-09)
    Although most women with luminal breast cancer do well on endocrine therapy alone, some will develop fatal recurrence thereby necessitating the need to prospectively determine those for whom additional cytotoxic therapy ...
  • Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. 

    Dunning, AM; Michailidou, K; Kuchenbaecker, KB; Thompson, D; French, JD; Beesley, J; Healey, CS; Kar, S; Pooley, KA; Lopez-Knowles, E; Dicks, E; Barrowdale, D; Sinnott-Armstrong, NA; Sallari, RC; Hillman, KM; Kaufmann, S; Sivakumaran, H; Moradi Marjaneh, M; Lee, JS; Hills, M; Jarosz, M; Drury, S; Canisius, S; Bolla, MK; Dennis, J; Wang, Q; Hopper, JL; Southey, MC; Broeks, A; Schmidt, MK; Lophatananon, A; Muir, K; Beckmann, MW; Fasching, PA; Dos-Santos-Silva, I; Peto, J; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Flyger, H; González-Neira, A; Perez, JI; Anton-Culver, H; Eunjung, L; Arndt, V; Brenner, H; Meindl, A; Schmutzler, RK; Brauch, H; Hamann, U; Aittomäki, K; Blomqvist, C; Ito, H; Matsuo, K; Bogdanova, N; Dörk, T; Lindblom, A; Margolin, S; Kosma, VM; Mannermaa, A; Tseng, CC; Wu, AH; Lambrechts, D; Wildiers, H; Chang-Claude, J; Rudolph, A; Peterlongo, P; Radice, P; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Henderson, BE; Goldberg, MS; Teo, SH; Yip, CH; Nord, S; Borresen-Dale, AL; Kristensen, V; Long, J; Zheng, W; Pylkäs, K; Winqvist, R; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; Figueroa, J; Sherman, ME; Czene, K; Darabi, H; Hollestelle, A; van den Ouweland, AM; Humphreys, K; Gao, YT; Shu, XO; Cox, A; Cross, SS; Blot, W; Cai, Q; Ghoussaini, M; Perkins, BJ; Shah, M; Choi, JY; Kang, D; Lee, SC; Hartman, M; Kabisch, M; Torres, D; Jakubowska, A; Lubinski, J; Brennan, P; Sangrajrang, S; Ambrosone, CB; Toland, AE; Shen, CY; Wu, PE; Orr, N; Swerdlow, A; McGuffog, L; Healey, S; Lee, A; Kapuscinski, M; John, EM; Terry, MB; Daly, MB; Goldgar, DE; Buys, SS; Janavicius, R; Tihomirova, L; Tung, N; Dorfling, CM; van Rensburg, EJ; Neuhausen, SL; Ejlertsen, B; Hansen, TV; Osorio, A; Benitez, J; Rando, R; Weitzel, JN; Bonanni, B; Peissel, B; Manoukian, S; Papi, L; Ottini, L; Konstantopoulou, I; Apostolou, P; Garber, J; Rashid, MU; Frost, D; Izatt, L; Ellis, S; Godwin, AK; Arnold, N; Niederacher, D; Rhiem, K; Bogdanova-Markov, N; Sagne, C; Stoppa-Lyonnet, D; Damiola, F; Sinilnikova, OM; Mazoyer, S; Isaacs, C; Claes, KB; De Leeneer, K; de la Hoya, M; Caldes, T; Nevanlinna, H; Khan, S; Mensenkamp, AR; Hooning, MJ; Rookus, MA; Kwong, A; Olah, E; Diez, O; Brunet, J; Pujana, MA; Gronwald, J; Huzarski, T; Barkardottir, RB; Laframboise, R; Soucy, P; Montagna, M; Agata, S; Teixeira, MR; Park, SK; Lindor, N; Couch, FJ; Tischkowitz, M; Foretova, L; Vijai, J; Offit, K; Singer, CF; Rappaport, C; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Imyanitov, EN; Hulick, PJ; Phillips, KA; Piedmonte, M; Mulligan, AM; Glendon, G; Bojesen, A; Thomassen, M; Caligo, MA; Yoon, SY; Friedman, E; Laitman, Y; Borg, A; von Wachenfeldt, A; Ehrencrona, H; Rantala, J; Olopade, OI; Ganz, PA; Nussbaum, RL; Gayther, SA; Nathanson, KL; Domchek, SM; Arun, BK; Mitchell, G; Karlan, BY; Lester, J; Maskarinec, G; Woolcott, C; Scott, C; Stone, J; Apicella, C; Tamimi, R; Luben, R; Khaw, KT; Helland, Å; Haakensen, V; Dowsett, M; Pharoah, PD; Simard, J; Hall, P; García-Closas, M; Vachon, C; Chenevix-Trench, G; Antoniou, AC; Easton, DF; Edwards, SL (2016-04)
    We analyzed 3,872 common genetic variants across the ESR1 locus (encoding estrogen receptor α) in 118,816 subjects from three international consortia. We found evidence for at least five independent causal variants, each ...
  • Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. 

    Ferreira, MA; Gamazon, ER; Al-Ejeh, F; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Arason, A; Arndt, V; Aronson, KJ; Arun, BK; Asseryanis, E; Azzollini, J; Balmaña, J; Barnes, DR; Barrowdale, D; Beckmann, MW; Behrens, S; Benitez, J; Bermisheva, M; Białkowska, K; Blomqvist, C; Bogdanova, NV; Bojesen, SE; Bolla, MK; Borg, A; Brauch, H; Brenner, H; Broeks, A; Burwinkel, B; Caldés, T; Caligo, MA; Campa, D; Campbell, I; Canzian, F; Carter, J; Carter, BD; Castelao, JE; Chang-Claude, J; Chanock, SJ; Christiansen, H; Chung, WK; Claes, KBM; Clarke, CL; EMBRACE Collaborators; GC-HBOC Study Collaborators; GEMO Study Collaborators; Couch, FJ; Cox, A; Cross, SS; Czene, K; Daly, MB; de la Hoya, M; Dennis, J; Devilee, P; Diez, O; Dörk, T; Dunning, AM; Dwek, M; Eccles, DM; Ejlertsen, B; Ellberg, C; Engel, C; Eriksson, M; Fasching, PA; Fletcher, O; Flyger, H; Friedman, E; Frost, D; Gabrielson, M; Gago-Dominguez, M; Ganz, PA; Gapstur, SM; Garber, J; García-Closas, M; García-Sáenz, JA; Gaudet, MM; Giles, GG; Glendon, G; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Greene, MH; Gronwald, J; Guénel, P; Haiman, CA; Hall, P; Hamann, U; He, W; Heyworth, J; Hogervorst, FBL; Hollestelle, A; Hoover, RN; Hopper, JL; Hulick, PJ; Humphreys, K; Imyanitov, EN; ABCTB Investigators; HEBON Investigators; BCFR Investigators; Isaacs, C; Jakimovska, M; Jakubowska, A; James, PA; Janavicius, R; Jankowitz, RC; John, EM; Johnson, N; Joseph, V; Karlan, BY; Khusnutdinova, E; Kiiski, JI; Ko, Y-D; Jones, ME; Konstantopoulou, I; Kristensen, VN; Laitman, Y; Lambrechts, D; Lazaro, C; Leslie, G; Lester, J; Lesueur, F; Lindström, S; Long, J; Loud, JT; Lubiński, J; Makalic, E; Mannermaa, A; Manoochehri, M; Margolin, S; Maurer, T; Mavroudis, D; McGuffog, L; Meindl, A; Menon, U; Michailidou, K; Miller, A; Montagna, M; Moreno, F; Moserle, L; Mulligan, AM; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nevelsteen, I; Nielsen, FC; Nikitina-Zake, L; Nussbaum, RL; Offit, K; Olah, E; Olopade, OI; Olsson, H; Osorio, A; Papp, J; Park-Simon, T-W; Parsons, MT; Pedersen, IS; Peixoto, A; Peterlongo, P; Pharoah, PDP; Plaseska-Karanfilska, D; Poppe, B; Presneau, N; Radice, P; Rantala, J; Rennert, G; Risch, HA; Saloustros, E; Sanden, K; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Sharma, P; Shu, X-O; Simard, J; Singer, CF; Soucy, P; Southey, MC; Spinelli, JJ; Spurdle, AB; Stone, J; Swerdlow, AJ; Tapper, WJ; Taylor, JA; Teixeira, MR; Terry, MB; Teulé, A; Thomassen, M; Thöne, K; Thull, DL; Tischkowitz, M; Toland, AE; Torres, D; Truong, T; Tung, N; Vachon, CM; van Asperen, CJ; van den Ouweland, AMW; van Rensburg, EJ; Vega, A; Viel, A; Wang, Q; Wappenschmidt, B; Weitzel, JN; Wendt, C; Winqvist, R; Yang, XR; Yannoukakos, D; Ziogas, A; Kraft, P; Antoniou, AC; Zheng, W; Easton, DF; Milne, RL; Beesley, J; Chenevix-Trench, G (2019-04-15)
    Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue ...
  • No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. 

    Easton, DF; Lesueur, F; Decker, B; Michailidou, K; Li, J; Allen, J; Luccarini, C; Pooley, KA; Shah, M; Bolla, MK; Wang, Q; Dennis, J; Ahmad, J; Thompson, ER; Damiola, F; Pertesi, M; Voegele, C; Mebirouk, N; Robinot, N; Durand, G; Forey, N; Luben, RN; Ahmed, S; Aittomäki, K; Anton-Culver, H; Arndt, V; Baynes, C; Beckman, MW; Benitez, J; Van Den Berg, D; Blot, WJ; Bogdanova, NV; Bojesen, SE; Brenner, H; Chang-Claude, J; Chia, KS; Choi, JY; Conroy, DM; Cox, A; Cross, SS; Czene, K; Darabi, H; Devilee, P; Eriksson, M; Fasching, PA; Figueroa, J; Flyger, H; Fostira, F; García-Closas, M; Giles, GG; Glendon, G; González-Neira, A; Guénel, P; Haiman, CA; Hall, P; Hart, SN; Hartman, M; Hooning, MJ; Hsiung, CN; Ito, H; Jakubowska, A; James, PA; John, EM; Johnson, N; Jones, M; Kabisch, M; Kang, D; Kosma, VM; Kristensen, V; Lambrechts, D; Li, N; Lindblom, A; Long, J; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Margolin, S; Matsuo, K; Meindl, A; Mitchell, G; Muir, K; Nevelsteen, I; van den Ouweland, A; Peterlongo, P; Phuah, SY; Pylkäs, K; Rowley, SM; Sangrajrang, S; Schmutzler, RK; Shen, CY; Shu, XO; Southey, MC; Surowy, H; Swerdlow, A; Teo, SH; Tollenaar, RA; Tomlinson, I; Torres, D; Truong, T; Vachon, C; Verhoef, S; Wong-Brown, M; Zheng, W; Zheng, Y; Nevanlinna, H; Scott, RJ; Andrulis, IL; Wu, AH; Hopper, JL; Couch, FJ; Winqvist, R; Burwinkel, B; Sawyer, EJ; Schmidt, MK; Rudolph, A; Dörk, T; Brauch, H; Hamann, U; Neuhausen, SL; Milne, RL; Fletcher, O; Pharoah, PD; Campbell, IG; Dunning, AM; Le Calvez-Kelm, F; Goldgar, DE; Tavtigian, SV; Chenevix-Trench, G (2016-05)
    BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, and previous ...
  • Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. 

    Woolf, DK; Li, SP; Detre, S; Liu, A; Gogbashian, A; Simcock, IC; Stirling, J; Kosmin, M; Cook, GJ; Siddique, M; Dowsett, M; Makris, A; Goh, V (2019)
    Background: Tumour heterogeneity is considered an important mechanism of treatment failure. Imaging-based assessment of tumour heterogeneity is showing promise but the relationship between these mathematically derived ...
  • Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. 

    Sonnenblick, A; Bailey, A; Uziely, B; Untch, M; Smith, I; Gianni, L; Baselga, J; Jackisch, C; Cameron, D; Bell, R; Zardavas, D; Al-Sakaff, N; Gelber, RD; Dowsett, M; Leyland-Jones, B; Piccart-Gebhart, MJ; DE Azambuja, E (2019-02)
    BACKGROUND/AIM: This study sought to determine whether an autoimmune background could identify patients with HER2-positive early breast cancer (EBC) who derive differential benefit from primary adjuvant trastuzumab-based ...
  • Night shift work and risk of breast cancer in women: the Generations Study cohort. 

    Jones, ME; Schoemaker, MJ; McFadden, EC; Wright, LB; Johns, LE; Swerdlow, AJ (2019-07)
    BACKGROUND: It is plausible that night shift work could affect breast cancer risk, possibly by melatonin suppression or circadian clock disruption, but epidemiological evidence is inconclusive. METHODS: Using serial ...
  • Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. 

    van Weverwijk, A; Koundouros, N; Iravani, M; Ashenden, M; Gao, Q; Poulogiannis, G; Jungwirth, U; Isacke, CM (2019-06-20)
    The different stages of the metastatic cascade present distinct metabolic challenges to tumour cells and an altered tumour metabolism associated with successful metastatic colonisation provides a therapeutic vulnerability ...
  • Dissecting PARP inhibitor resistance with functional genomics. 

    Pettitt, SJ; Lord, CJ (2019-02)
    The poly-(ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib was the first licenced cancer drug that targeted an inherited form of cancer, namely ovarian cancers caused by germline BRCA1 or BRCA2 gene mutations. ...
  • Beyond DNA repair: the novel immunological potential of PARP inhibitors. 

    Chabanon, RM; Soria, J-C; Lord, CJ; Postel-Vinay, S (2019)
    Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, ...

View more